JP
Jayson Punwani
Managing Director at Abingworth
Menlo Park, California
Overview
Jayson Punwani is the Managing Director at Abingworth, a venture capital firm in Menlo Park, California. With a background in biochemistry and molecular biology, he has successfully invested in companies like Xilio Therapeutics (Series C) and StrideBio (Series A), demonstrating expertise in the biotechnology sector and leading investments in innovative start-ups.
Work Experience
Managing Director
2022 - Current
Board director: Q32 Bio, Escient Pharmaceuticals, Addition Therapeutics
Partner
2021 - 2022
Board director: Q32 Bio
Interim CEO
2021 - 2021
Co-founder
2019 - 2021
Partner
2017 - 2020
Board director: ArmaGen (Acquired by JCR Pharma), Coho Therapeutics (co-founder), Palleon Pharma, StrideBio, VelosBio (Acquired by Merck), Xilio Therapeutics
Principal
2011 - 2017
Engaged in investment activities for a life science-focused VC firm with >$450MM in assets under management. Integral member of investment team for joint venture with Chiesi Venture Fund. Select Board observer roles: Aura Biosciences, Balance Therapeutics, CardioDx, CoLucid Pharmaceuticals, Lumena, Glycomine and OrphoMed.
Bridging the Early-Stage Funding Gap.
Director
2010 - 2012
Technology Development @ OTD
2009 - 2010
Postdoctoral Research Associate
2008 - 2010